Cargando…
Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration
Wet age-related macular degeneration (AMD) is an end-stage event in a complex pathogenesis of macular degeneration, involving the abnormal growth of blood vessels at the retinal pigment epithelium driven by vascular endothelial growth factor (VEGF). Current therapies seek to interrupt VEGF signaling...
Autores principales: | Wu, Tony, Liu, Chang, Kannan, Rangaramanujam M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609940/ https://www.ncbi.nlm.nih.gov/pubmed/37896188 http://dx.doi.org/10.3390/pharmaceutics15102428 |
Ejemplares similares
-
Future Therapies of Wet Age-Related Macular Degeneration
por: Ishikawa, Makoto, et al.
Publicado: (2015) -
Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015) -
Imaging of Wet Age-Related Macular Degeneration
por: Kenan, Damer
Publicado: (2016) -
Pegaptanib in the treatment of wet, age-related macular degeneration
por: Vinores, Stanley A
Publicado: (2006) -
Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
por: Garba, Adinoyi O., et al.
Publicado: (2010)